Clinical Trial

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Name: Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC — clinical trial record (NCT06897046)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This project intends to study the efficacy and safety of Iparomlimab and Tuvonralimab with or without chemotherapyin the perioperative treatment of NSCLC

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-03-20.

Status change: Not Yet Recruiting → Recruiting 2025-07-31

Trial Details

NCT Number	NCT06897046
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	Non-small Cell Lung Cancer (NSCLC), II-IIIB
Enrollment	90 participants
Start Date	2025-07-30
Primary Completion	2027-02-25 (estimated)
Study Completion	2027-05-25 (estimated)
Updated on ClinicalTrials.gov	2025-08-01